Logo image of ASMB

ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

USA - NASDAQ:ASMB - US0453962070 - Common Stock

30.89 USD
+1.09 (+3.66%)
Last: 10/28/2025, 8:00:01 PM
30.89 USD
0 (0%)
After Hours: 10/28/2025, 8:00:01 PM
Fundamental Rating

3

Overall ASMB gets a fundamental rating of 3 out of 10. We evaluated ASMB against 534 industry peers in the Biotechnology industry. The financial health of ASMB is average, but there are quite some concerns on its profitability. ASMB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ASMB has reported negative net income.
ASMB had a negative operating cash flow in the past year.
ASMB had negative earnings in each of the past 5 years.
ASMB had negative operating cash flow in 4 of the past 5 years.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

ASMB has a Return On Assets (-48.23%) which is in line with its industry peers.
ASMB's Return On Equity of -215.27% is on the low side compared to the rest of the industry. ASMB is outperformed by 68.16% of its industry peers.
Industry RankSector Rank
ROA -48.23%
ROE -215.27%
ROIC N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASMB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ASMB has been increased compared to 5 years ago.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ASMB has an Altman-Z score of -11.78. This is a bad value and indicates that ASMB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.78, ASMB is doing worse than 75.47% of the companies in the same industry.
ASMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.78
ROIC/WACCN/A
WACC8.65%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ASMB has a Current Ratio of 1.64. This is a normal value and indicates that ASMB is financially healthy and should not expect problems in meeting its short term obligations.
ASMB has a worse Current ratio (1.64) than 80.15% of its industry peers.
A Quick Ratio of 1.64 indicates that ASMB should not have too much problems paying its short term obligations.
ASMB's Quick ratio of 1.64 is on the low side compared to the rest of the industry. ASMB is outperformed by 79.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.64
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.21% over the past year.
Looking at the last year, ASMB shows a very strong growth in Revenue. The Revenue has grown by 54.77%.
ASMB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)38.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.83%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%12.81%

3.2 Future

Based on estimates for the next years, ASMB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.41% on average per year.
ASMB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y40.99%
EPS Next 2Y26.36%
EPS Next 3Y24.56%
EPS Next 5Y13.41%
Revenue Next Year19.08%
Revenue Next 2Y-8.06%
Revenue Next 3Y46.05%
Revenue Next 5Y19.24%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASMB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

ASMB's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.36%
EPS Next 3Y24.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (10/28/2025, 8:00:01 PM)

After market: 30.89 0 (0%)

30.89

+1.09 (+3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05
Inst Owners23.27%
Inst Owner Change0.95%
Ins Owners4.52%
Ins Owner Change0%
Market Cap409.60M
Revenue(TTM)33.25M
Net Income(TTM)-38964000
Analysts85.45
Price Target38.96 (26.12%)
Short Float %18.83%
Short Ratio9.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.39%
Min EPS beat(2)4.47%
Max EPS beat(2)28.31%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)4.47%
Max EPS beat(4)28.31%
EPS beat(8)7
Avg EPS beat(8)19.79%
EPS beat(12)7
Avg EPS beat(12)12.3%
EPS beat(16)10
Avg EPS beat(16)11.95%
Revenue beat(2)2
Avg Revenue beat(2)37.63%
Min Revenue beat(2)24.54%
Max Revenue beat(2)50.71%
Revenue beat(4)3
Avg Revenue beat(4)23.01%
Min Revenue beat(4)-22.37%
Max Revenue beat(4)50.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.13%
PT rev (3m)20.63%
EPS NQ rev (1m)-9.63%
EPS NQ rev (3m)41.53%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)20.98%
Revenue NQ rev (1m)1.85%
Revenue NQ rev (3m)16.35%
Revenue NY rev (1m)2.44%
Revenue NY rev (3m)14.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.32
P/FCF N/A
P/OCF N/A
P/B 22.63
P/tB 22.63
EV/EBITDA N/A
EPS(TTM)-5.58
EYN/A
EPS(NY)-2.71
Fwd EYN/A
FCF(TTM)-4.21
FCFYN/A
OCF(TTM)-4.21
OCFYN/A
SpS2.51
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.23%
ROE -215.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.64
Altman-Z -11.78
F-Score3
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)32.95%
Cap/Depr(5y)216.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.83%
EPS Next Y40.99%
EPS Next 2Y26.36%
EPS Next 3Y24.56%
EPS Next 5Y13.41%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%12.81%
Revenue Next Year19.08%
Revenue Next 2Y-8.06%
Revenue Next 3Y46.05%
Revenue Next 5Y19.24%
EBIT growth 1Y13.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.88%
EBIT Next 3Y39.36%
EBIT Next 5Y28.3%
FCF growth 1Y26.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.64%
OCF growth 3YN/A
OCF growth 5YN/A

ASSEMBLY BIOSCIENCES INC / ASMB FAQ

What is the ChartMill fundamental rating of ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ASMB.


What is the valuation status of ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ChartMill assigns a valuation rating of 1 / 10 to ASSEMBLY BIOSCIENCES INC (ASMB). This can be considered as Overvalued.


How profitable is ASSEMBLY BIOSCIENCES INC (ASMB) stock?

ASSEMBLY BIOSCIENCES INC (ASMB) has a profitability rating of 0 / 10.


Can you provide the financial health for ASMB stock?

The financial health rating of ASSEMBLY BIOSCIENCES INC (ASMB) is 5 / 10.


Can you provide the expected EPS growth for ASMB stock?

The Earnings per Share (EPS) of ASSEMBLY BIOSCIENCES INC (ASMB) is expected to grow by 40.99% in the next year.